NCT02110966View on ClinicalTrials.gov

Mepivacaine-Tramadol on the Success of Inferior Alveolar Nerve Block in Symptomatic Irreversible Pulpitis

PHASE4CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
Symptomatic Irreversible Pulpitis
Interventions
DRUG

Mepivacaine

Drug: Tramadol 1.8 ml of Mepivacaine 2% epinephrine 1:100000.

DRUG

Mepivacaine plus Tramadol

0.5 ml of Tramadol mixed with 1.3 ml of Mepivacaine.

Trial Locations (1)

78290

Endodontics Master Degree program, Dentistry Faculty, San Luis Potosi University, San Luis Potosí City

All Listed Sponsors
lead

Daniel Chavarría Bolaños

OTHER

NCT02110966 - Mepivacaine-Tramadol on the Success of Inferior Alveolar Nerve Block in Symptomatic Irreversible Pulpitis | Biotech Hunter | Biotech Hunter